心外膜与心包脂肪的心血管意义及遗传学
EPAT多基因评分在FinnGen中与上述疾病及房颤、卒中相关。
要点
- EPAT与 incident 心衰、2型糖尿病、冠心病相关,但校正内脏脂肪后关联不再显著。
- EPAT多基因评分与2型糖尿病、心衰、冠心病、房颤及卒中相关。
- EPAT的心血管关联可能反映代谢不健康肥胖表型,而非局部旁分泌效应。
核心结论
- EPAT与 incident 心血管疾病相关,但可能主要反映与腹部内脏脂肪相似的代谢不健康肥胖表型。
主要发现
- EPAT与男性(β=+0.78 SD;P<3×10^-324)、年龄(Pearson r=0.15;P=9.3×10^-229)、BMI(r=0.47;P<3×10^-324)和内脏脂肪(r=0.72;P<3×10^-324)正相关。
- EPAT在 prevalent 心衰(β=+0.46 SD)和2型糖尿病(β=+0.56)中升高程度高于冠心病(β=+0.23)或房颤(β=+0.18)。
- EPAT与 incident 心衰(HR 1.29/ +1 SD;95%CI 1.17-1.43)、2型糖尿病(HR 1.63;95%CI 1.51-1.76)和冠心病(HR 1.19;95%CI 1.11-1.28)相关,但校正内脏脂肪后不再显著。
- 识别出7个EPAT遗传位点,涉及脂肪细胞形态和棕色脂肪生成的转录调控因子(EBF1、EBF2、CEBPA)及内脏肥胖调控因子(WARS2、TRIB2)。
- EPAT多基因评分每增加1 SD,与2型糖尿病(OR 1.06;95%CI 1.05-1.07;P=3.6×10^-44)、心衰(OR 1.05;95%CI 1.04-1.06;P=4.8×10^-15)、冠心病(OR 1.04;95%CI 1.03-1.05;P=1.4×10^-17)、房颤(OR 1.04;95%CI 1.03-1.06;P=7.6×10^-12)及卒中(OR 1.02;95%CI 1.01-1.03;P=3.5×10^-3)相关。
临床怎么用
- 心外膜与心包脂肪增多应视为代谢不健康肥胖的标志,评估心血管风险时需结合腹部内脏脂肪等整体肥胖指标。
- EPAT多基因评分与多种心血管代谢疾病相关,但当前尚不用于临床风险分层。
局限性
- EPAT与心血管疾病的关联在校正腹部内脏脂肪后不再显著,提示EPAT的独立效应有限。
- 研究为观察性设计,无法确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Epicardial and pericardial adipose tissue (EPAT) has been associated with cardiovascular diseases such as atrial fibrillation or flutter (AF) and coronary artery disease (CAD), but studies have been limited in sample size or drawn from selected populations. It has been suggested that the association between EPAT and cardiovascular disease could be mediated by local or paracrine effects. OBJECTIVE: To evaluate the association of EPAT with prevalent and incident cardiovascular disease and to elucidate the genetic basis of EPAT in a large population cohort. DESIGN, SETTING, AND PARTICIPANTS: A deep learning model was trained to quantify EPAT area from 4-chamber magnetic resonance images using semantic segmentation. Cross-sectional and prospective cardiovascular disease associations were evaluated, controlling for sex and age. Prospective associations were additionally controlled for abdominal visceral adipose tissue (VAT) volumes. A genome-wide association study was performed, and a polygenic score (PGS) for EPAT was examined in independent FinnGen cohort study participants. Data analyses were conducted from March 2022 to December 2023. EXPOSURES: The primary exposures were magnetic resonance imaging-derived continuous measurements of epicardial and pericardial adipose tissue area and visceral adipose tissue volume. MAIN OUTCOMES AND MEASURES: Prevalent and incident CAD, AF, heart failure (HF), stroke, and type 2 diabetes (T2D). RESULTS: After exclusions, this study included 44 475 participants (mean [SD] age, 64.1 [7.7] years; 22 972 female [51.7%]) from the UK Biobank. Cross-sectional and prospective cardiovascular disease associations were evaluated for a mean (SD) of 3.2 (1.5) years of follow-up. Prospective associations were additionally controlled for abdominal VAT volumes for 38 527 participants. A PGS for EPAT was examined in 453 733 independent FinnGen cohort study participants. EPAT was positively associated with male sex (β = +0.78 SD in EPAT; P < 3 × 10-324), age (Pearson r = 0.15; P = 9.3 × 10-229), body mass index (Pearson r = 0.47; P < 3 × 10-324), and VAT (Pearson r = 0.72; P < 3 × 10-324). EPAT was more elevated in prevalent HF (β = +0.46 SD units) and T2D (β = +0.56) than in CAD (β = +0.23) or AF (β = +0.18). EPAT was associated with incident HF (hazard ratio [HR], 1.29 per +1 SD in EPAT; 95% CI, 1.17-1.43), T2D (HR, 1.63; 95% CI, 1.51-1.76), and CAD (HR, 1.19; 95% CI, 1.11-1.28). However, the associations were no longer significant when controlling for VAT. Seven genetic loci were identified for EPAT, implicating transcriptional regulators of adipocyte morphology and brown adipogenesis (EBF1, EBF2, and CEBPA) and regulators of visceral adiposity (WARS2 and TRIB2). The EPAT PGS was associated with T2D (odds ratio [OR], 1.06; 95% CI, 1.05-1.07; P =3.6 × 10-44), HF (OR, 1.05; 95% CI, 1.04-1.06; P =4.8 × 10-15), CAD (OR, 1.04; 95% CI, 1.03-1.05; P =1.4 × 10-17), AF (OR, 1.04; 95% CI, 1.03-1.06; P =7.6 × 10-12), and stroke in FinnGen (OR, 1.02; 95% CI, 1.01-1.03; P =3.5 × 10-3) per 1 SD in PGS. CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that epicardial and pericardial adiposity was associated with incident cardiovascular diseases, but this may largely reflect a metabolically unhealthy adiposity phenotype similar to abdominal visceral adiposity.
引用
- Rämö JT, Kany S, Hou CR, et al. Cardiovascular Significance and Genetics of Epicardial and Pericardial Adiposity. JAMA Cardiol. 2024. PMID: 38477908. doi:10.1001/jamacardio.2024.0080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。